文献速递毛发、甲与色素性疾病

微针透皮递送复方倍他米松治疗斑秃的随机对照试验

Microneedle transdermal delivery of compound betamethasone in alopecia areata-A randomized controlled trial.
PubMed 文献 · J Am Acad Dermatol · 2024-10-10

本研究纳入80例SALT评分<50的轻中度斑秃患者,随机分组比较微针透皮递送与皮损内注射复方倍他米松的疗效与疼痛。治疗3个月后两组SALT评分下降无统计学差异,微针组疼痛视觉模拟评分显著低于注射组(4.000±1.174 vs 5.281±2.098,P=.0047)。

要点

  • 微针透皮递送复方倍他米松治疗轻中度斑秃疗效与皮损内注射相当。
  • 微针组疼痛评分显著低于传统皮损内注射组。
  • 研究仅针对轻中度斑片状斑秃,重度病例数据有限。

核心结论

  • 微针透皮递送复方倍他米松治疗轻中度斑片状斑秃疗效与皮损内注射相当,且疼痛更轻。

研究设计与样本

  • 随机对照试验,纳入80例SALT评分<50的斑秃患者,两组每月接受复方倍他米松注射,A组皮损内注射,B组微针透皮递送。

主要发现

  • 治疗3个月后A组SALT平均下降7.000±4.5017,B组8.075±8.014,无统计学差异。
  • SALT30/50/75/90缓解率A组为92.50/90.00/57.50/42.50%,B组为95.00/87.50/72.50/40%,无显著差异。
  • B组疼痛视觉模拟评分显著低于A组(4.000±1.174 vs 5.281±2.098,P=.0047)。

关键数值与推荐

  • 主要结局为治疗3个月后SALT评分下降。
  • 两组基线SALT评分:A组9.250±5.300,B组10.65±9.445。

临床怎么用

  • 对轻中度斑片状斑秃,可考虑微针透皮递送复方倍他米松以减轻注射疼痛。

局限性

  • 研究聚焦轻中度斑片状斑秃,对重度病例的启示有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Alopecia areata (AA) places a considerable burden on patients. While intralesional glucocorticoid injection is an important therapy, it can cause severe pain. OBJECTIVE: To compare the efficacy and pain levels of microneedle transdermal delivery of compound betamethasone versus traditional intralesional injection in mild-to-moderate AA. METHODS: We conducted a randomized controlled trial in AA patients with a Severity of Alopecia Tool (SALT) score <50. Both groups received monthly compound betamethasone injections: group A via intralesional injections and group B via transdermal microneedle delivery. The primary outcome was the reduction in SALT score after 3 months. RESULTS: With 80 patients enrolled, baseline SALT scores were similar between group A (9.250 ± 5.300) and group B (10.65 ± 9.445). After 3 months, the mean SALT reduction was 7.000 ± 4.5017 in group A and 8.075 ± 8.014 in group B, with no statistical difference. Remission rates for SALT30/50/75/90 were 92.50/90.00/57.50/42.50% in group A and 95.00/87.50/72.50/40% in group B, with no significant difference. Group B had a significantly lower visual analog scale pain score than group A (4.000 ± 1.174 vs 5.281 ± 2.098, P = .0047). LIMITATIONS: The study focused on mild-to-moderate patchy AA, limiting insights into severe cases. CONCLUSION: Microneedle transdermal delivery of compound betamethasone in mild-to-moderate patchy AA demonstrates efficacy comparable to traditional intralesional injection with reduced pain.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Qiao R, Zhu J, Fang J, et al. Microneedle transdermal delivery of compound betamethasone in alopecia areata-A randomized controlled trial. J Am Acad Dermatol. 2024. PMID: 39393548. doi:10.1016/j.jaad.2024.09.059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。